NCT02147067View on ClinicalTrials.gov

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)

PHASE2CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2018

Study Completion Date

June 30, 2018

Conditions

Microvascular Angina

Interventions

DRUG

Ranolazine

Ranolazine 1,000 mg twice daily

DRUG

Placebo

Placebo

Trial Locations (1)

30322

Emory University, Atlanta

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Emory University

OTHER